Arkansas-based Onterris reported "good" air quality after a giant warehouse fire in Los Angeles. Some experts and activists say the testing is inadequate.

It isn't approved by the FDA, but we found an experimental weight-loss drug called retatrutide for sale at a local convenience store.

Investigations are underway into possible fraudulent activity at some of these kinds of facilities across New York, CBS News has learned.

Los Angeles building inspectors have launched an investigation into alleged unpermitted construction at a warehouse that erupted in flames last week - its second fire in two years.

CBS News watched bystander video of the deadly ICE shooting in Minneapolis frame-by-frame with retired ICE agent Eric Balliet​ to discuss the tactics used. He raised a few key points that dispute the DHS narrative of what happened.

The FDA and the manufacturer were alerted to Profemur titanium hips breaking inside U.S. patients as of 2005. It took 15 years to recall the devices. Many fractures could have been avoided.

There are 4,207 bridges in the U.S. that allow ships to pass under them. Of those, only 36% are described as having functional pier protection.

A dental device called AGGA has been used on about 10,000 patients without FDA approval or proof that it works. In lawsuits, patients report irreparable harm. The AGGA's inventor and manufacturer have denied all liability in court.

Mo Strategies, started by former Trump campaign and administration officials, recently expanded its practice into the lucrative world of pardon lobbying.

President Trump's investment accounts traded between $212 million and $695 million in stocks and other securities in the first three months of the year - an unprecedented sum for a sitting president.

Former CIA Director John Brennan is the subject of two criminal probes being led by the Miami-area U.S. Attorney's Office.

Two companies dominate U.S. dialysis services, and a CBS News review of federal data found one-third of dialysis clinics failed to meet federal standards this year.

The Trump administration's elevation of Dr. Tracy Beth Høeg to lead a high-profile office within the Food and Drug Administration is raising alarm among multiple senior FDA officials.